Show simple item record

dc.contributor.authorQuartuccio, N.
dc.contributor.authorSalem, Ahmed
dc.contributor.authorLaudicella, R.
dc.contributor.authorSpataro, A.
dc.contributor.authorChiaravalloti, A.
dc.contributor.authorCaobelli, F.
dc.contributor.authorCistaro, A.
dc.contributor.authorAlongi, P.
dc.contributor.authorEvangelista, L.
dc.date.accessioned2021-04-20T08:08:24Z
dc.date.available2021-04-20T08:08:24Z
dc.date.issued2021en
dc.identifier.citationQuartuccio N, Salem A, Laudicella R, Spataro A, Chiaravalloti A, Caobelli F, et al. The role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic review. Nucl Med Commun. 2021.en
dc.identifier.pmid33741854en
dc.identifier.doi10.1097/mnm.0000000000001407en
dc.identifier.urihttp://hdl.handle.net/10541/623953
dc.description.abstractAim: 18F-Fluorodeoxyglucose (FDG) PET imaging may play an important role in the restaging of patients with small-cell lung cancer (SCLC),, nevertheless, a systematic review of literature was still missing in this setting. The aim of this review was to summarize the evidence on literature regarding the utility of 18F-FDG PET imaging in restaging patients with SCLC. Methods: A literature search was performed to retrieve original studies using 18F-FDG PET or 18F-FDG PET/computed tomography (CT) in a minimum of 10 patients with SCLC at restaging. Results: The selected literature (17 studies) was discussed in four sections: detection rate, impact on management, prediction of prognosis and evaluation of the response to therapy. According to the literature, PET imaging may result in discordance with conventional imaging, mainly contrast-enhanced CT (ceCT), and detect additional lesions in a certain proportion of cases, leading to upstaging or downstaging. A variable level of disagreement between PET and conventional imaging has been reported also in the evaluation of response to therapy. A positive PET study is associated with shorter survival, especially in the presence of distant metastases. According to some studies, semiquantitative parameters are also inversely associated with overall survival and progression-free survival. Although the retrieved articles proved the utility of 18F-FDG PET imaging in each clinical setting, literature is still limited. Conclusions: This review encourages the use of 18F-FDG PET imaging, especially in conjunction with ceCT in recurrent SCLC patients. Further level I evidence is needed to further assess the diagnostic and prognostic capability of 18F-FDG PET/ceCT findings in SCLC.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1097/mnm.0000000000001407en
dc.titleThe role of 18F-Fluorodeoxyglucose PET/CT in restaging patients with small cell lung cancer: a systematic reviewen
dc.typeArticleen
dc.contributor.departmentNuclear Medicine Unit, ARNAS Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italyen
dc.identifier.journalNuclear Medicine Communicationsen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record